Gene Therapy Was Hailed as a Revolution. Then Came the Bill.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Abstract:
      More drugmakers are betting gene therapies will have a big impact on patients and profits, with Pfizer Inc. last month agreeing to collaborate with Paris-based Vivet Therapeutics on a treatment for a rare liver disorder. After just a handful of patients got Strimvelis, a treatment for an immune disorder that cost about $675,000, GlaxoSmithKline Plc offloaded it to Orchard Therapeutics Plc. Related therapies that alter patients' immune cells to fight cancer, like Novartis's Kymriah, have also struggled. [Extracted from the article]
    • Abstract:
      Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)